Treatment in Schizophrenia: Factors For Adherence: Francisca Caiado de Bragança

2019/2020
Francisca Caiado de Bragança

Treatment in Schizophrenia: factors for adherence
Fevereiro, 2020
Mestrado Integrado em Medicina
Área: Psiquiatria e Saúde Mental

Tipologia: Monografia
Trabalho efetuado sob a Orientação de:

Professor Doutor Manuel António Fernandez Esteves
Trabalho organizado de acordo com as normas da revista:

Comprehensive Psychiatry
Fevereiro, 2020
Aos meus pais
Francisca Caiado de Bragança1, Manuel António Fernandez Esteves2

1
Faculty of Medicine, University of Porto, Porto, Portugal; Alameda Prof. Hernâni
Monteiro, 4200-319 PORTO, Porto, Portugal
2
Department of Clinical Neuroscience and Mental Health, Faculty of Medicine, University
of Porto, Porto, Portugal; Alameda Prof. Hernâni Monteiro, 4200-319 PORTO, Porto,
Portugal
Corresponding author:
Faculdade de Medicina da Universidade do Porto
Alameda Prof. Hernâni Monteiro, 4200-319 PORTO, Porto, Portugal
E-mail: franciscabraganca@hotmail.com
1
Abstract
This narrative review analyzes the existing scientific evidence on factors related
to medication adherence in schizophrenia.
Using PubMed as the database, a research was conducted targeting articles
published between 2009 and 2019, written in English or Portuguese, about predictors of
antipsychotic compliance in schizophrenia.
Factors affecting adherence have been generally subdivided into 4 categories:
disease-related, patient-related, medication-related and environmental-related. Factors
which were found to be consistently associated with poor adherence include poverty,
high symptom burden, high levels of hostility, poor insight, presence of substance abuse,
negative attitudes toward medication and antipsychotic side-effects. On the other hand,
variables such as neurocognitive dysfunction, type of antipsychotic, social support and
demographic parameters often yielded contradictory results.
Variables consistently associated with non-adherence should be assessed in
clinical practice and strategies put in place to correct them or dampen their effect. Since
conflicting results are often found regarding several studied variables, future research
should aim at identifying further predictors of adherence in order to better guide clinicians
and maximize the patient’s benefit of treatment.
Keywords: schizophrenia; adherence; antipsychotics.
2
1. Introduction
Schizophrenia is a disabling chronic illness that affects aproximatelly 0,5%-0,7%

of the adult population worldwide.1 Typically developing in late adolescence and early
adult life, it is caractherized by cognitive changes, lack of insight, and both positive and
negative symptoms, reflecting, respectively, a distortion and excess or a reduction in
normal functions.2 3 4
The primary treatment, adressing symptom burden and relapse
5
risk, includes both antipsychotic medication and psychossocial interventions, such as
cognitive-behavioral, compliance and family therapy and psychoeducation.2 4
Adherence to treatment is not an all or nothing phenomenon.6 Although both
adherence and compliance are plausible terms to describe the extent to which a patient
takes the medication prescribed by an healthcare provider, some authors prefer the term
adherence, as compliance generally involves deliberate treatment engagement. As the
two may be imperfect, both will be used interchangeably in this review.
Since schizophrenia is a chronic mental illness and adherence tends to be worse
with a prolonged disease course, non-adherence to antipsychotics is one of the most
important aspects of treatment.7 8
Patients’ low insight for the disease makes this
problem even more pronounced, with the decreased motivation to be treated being the
cause of highly detrimental consequences to the patient.8
In the literature, poor adherence in schizophrenia has been shown to be a strong
predictor of relapse, which is two to five times more likely to occur in non-compliant
patients.9 Non-adherence has also been associated with poor symptom outcome,
substance abuse, longer inpatient treatment, increased re-hospitalization, social
alienation, arrest, violence and greater economic burden.4 10 Besides this, non-adherent
patients are more likely to suffer from neurocognitive, occupational and social
dysfunction and ultimately to become a danger to themselves and others.11 12
In this setting, rates of non-adherence vary between 70% to 95%,13 although
naturalistic studies point to rates between 25 to 50%.14 In the CATIE study, a double-
blind trial that included 1493 patients, 74% of patients discontinued their medication
within 18 months, with no distinction between first and second generation
antipsychotics.3
Medication adherence is, in this way, a central aspect in the management of
these patients, and the factors affecting it have been studied for several years now.10
While for some the evidence consistently points to a direction of impact, for others the
results are many times inconsistent and contraditory.7 Putative predictors have been
generally categorized as disease-related, medication-related, environmental-related and
patient-related.14 The aim of this narrative review is to study how these factors affect
antipsychotic adherence in schizophrenia.
3
2. Methods
A research was conducted using the PUBMED database on the 10th September
2019, using the following query: ((((("schizophrenia"[MeSH Terms]) OR schizophre*))
AND ((("risk factors"[MeSH Terms]) OR predictors) OR reasons)) AND (((("treatment
adherence and compliance"[MeSH Terms])) OR "medication adherence"[MeSH Terms])
OR non adherence)) AND "antipsychotic agents"[MeSH Terms]. Articles were included
if written in English or Portuguese, published between 2009 and 2019, related to
humans.
The database returned a total of 181 references. After reading the title and
abstract, 115 articles were excluded for not being related to the theme. After the full
reading of the remaining 66 articles, 27 were excluded due to information that did not
apply to this study. To this total of 39 articles, 10 were added after a hand search of
relevant content found in references of selected articles. Thus, 49 articles were included
in this review.
4
3. Results
3.1. Disease-related factors
3.1.1. Illness duration
A shorter illness duration was found to be significantly associated with higher

rates of treatment discontinuation.5 In fact, patients with less than a five-year disease
course were found to be 2,7 times more likely to discontinue medication in comparison
to those with a course of over five years.5 Patients early in the course of disease seem
to have less insight, which is a strong predictor of non-adherence. However, illness
duration may also act as a proxy for other factors such as duration of maintenance
therapy.9 A longer duration of maintenance therapy has been shown to predict higher
adherence.15
3.1.2. Symptomology
The efficacy of antipsychotics in decreasing symptom burden is consistently

considered the core driver of the patient’s decision to comply with therapy.16 Studies go
further to state that symptomatic worsening during treatment is a stronger predictor of
discontinuation than medication intolerance.16 17
However, the degree of improvement in specific symptom clusters appear to be
more relevant in this behavior.17 Positive symptoms improvement has been pointed as
the most important symptom cluster predictor of treatment compliance.16 17 18 19 Besides
this cluster, only improvement in hostility levels and depressive symptoms predicted
adherence.17 Hallucinations and delusions of grandiosity impair the patient’s ability of
acknowledging the need to take the medication, making them reluctant to adhere.20 On
the other hand, improvement of negative symptoms hasn’t been a consistent predictor
of adherence.17 20
The positive valorization of symptoms has been an understudied subject, since
most patients seeking treatment refer more detrimental than advantageous effects.21
However, positive attitudes or ambivalence toward symptoms exists and have been
found more frequently in positive symptoms such as hallucinations and delusions.21 22
Some patients describe psychosis as fascinating, with an undisputable risk of attachment

to their delusional narratives.21 22
Paranoid patients convinced to be in possession of
special powers have high self-esteem, which can be a barrier to comply with treatment.22
Auditory hallucinations of benevolent content have been associated with decreased
5
compliance, especially when patients perceive paranoia as a survival strategy.21 22
A
study assessing the way patients perceive the possible gain from illness showed that
28% of patients discontinue their medication due to increased necessity of “importance
and power”, desire of “becoming another person” or “missing voices”.21 It is, thus, crucial
to assess how patients feel about their symptoms, in order to better guide the choice of
therapy.22
3.1.3. Neurocognitive dysfunction
Cognitive dysfunction is a robust feature of schizophrenia and has been pointed

out as a strong predictor of functional outcome,7 although there is still debate as whether
it does so independently or through non-compliance.14 Though studies assessing
neurocognition and adherence have reached different conclusions,7 14 15
memory
impairment and executive dysfunction have been found to be the most relevant
predictors of non-adherence in schizophrenia.14
In the memory field, adherent patients exhibit an overall better memory
performance, especially in verbal memory,14 while non-adherent patients have a worse
immediate recall ability, which hinders their capacity to comply.14 In fact, forgetting to
take the medication has been reported as the most frequent reason for non-adherent
behavior.23 9
In relation to executive functioning, patients that don’t adhere to antipsychotic
medication show significantly lower scores in tests evaluating attention, abstraction, and
cognitive flexibility.14 15
They also display impaired task-shifting abilities, which reflects
dysfunction in domains such as planning, problem solving and conceptualization,14 and
this has also been correlated to non-adherence.15
Other studies, however, have reached opposite conclusions, with non-adherent
patients exhibiting a higher level of neurocognition, exemplified by better verbal learning
and memory skills, executive functions and a higher IQ.7 Authors speculate that patients
with a higher cognitive performance may have a stronger belief in their ability to cope
without medication, and hence choose to discontinue it.7
In the field of language, verbal fluency has been found to be one the most
impaired cognitive domains in schizophrenia.15 A study has found that language
impairment, reflected by poor performances in verbal fluency tests, conferred a moderate
risk for non-adherence.15
Despite the debate around this topic, it is generally accepted that cognitive
dysfunction in schizophrenia impacts adherence both through decreased motivation and
impaired ability to engage in therapy.14
6
The premorbid functioning level of a patient who develops schizophrenia and its
impact on adherence is understudied and subject to conjecture.14 Those with higher
premorbid intellectual function, itself affected by the neurodevelopmental nature of
schizophrenia, are thought to better deal with the neural insult of the disease.24 An
improved cognitive reserve is thought to increase the ability to inhibit the abnormal neural
processes responsible for psychotic symptoms.24 Thus, it possibly translates into a
diminished symptom burden, which by itself improves adherence.14
3.1.4. Insight level
The multidimensional concept of insight includes the awareness of being ill, the
recognition of symptoms, the ability to attribute deficits to the disease and the
understanding of the need for treatment.25 26
The level of insight may be modulated by
the presence of neurocognitive deficits or coping mechanisms.25 18 In the literature, low
insight has been consistently associated with non-adherence.19 27 7 28 29
Patients with preserved insight are more able to lable psychotic symptoms as
pathological, have a greater awareness of the social consequences of the disease and
are ultimately more likely to find the treatment both reasonable and necessary.7 11 18
It is also noteworthy that, although impaired insight is a well-established predictor
of non-adherence, patients taking long-acting injectable antipsychotics may be adherent
despite having poor insight, making these medications a reasonable option to improve
outcomes in patients whose insight is impaired.25
3.1.5. Hostility
Patients exhibiting high hostility were found to be less adherent to treatment.30 25

29 28
Hostility and insight are often seen as concomitant factors impacting adherence and
for this reason should be assessed together.29 This is further supported by the fact that
hostile patients with decreased insight showed over 90% probability of not complying
with medication.25 Hence, hostility is found to be both a predictor of non-adherence and
an amplifier of the correlation between insight and adherence.25
7
3.2. Patient-related factors
3.2.1. Socio-demographics
There are conflicting results regarding the relationship between demographic

variables and compliance with treatment in schizophrenic patients.30
While some don’t find an association between the patient’s age and adherence
behavior,25 27
an older age has been associated with decreased compliance with
treatment.31 This latter finding has been attributed to a higher pill burden in this age
group, in addition to common memory and executive functioning deficits.31 However,
other studies find opposite results,32 15 3
with increasing age having a positive influence
on compliance.3 23 33
The decreased independence and mobility of older individuals
seems to ease clinical monitoring, contributing to higher adherence rates.34 In the same
line of thought, patients who are early in their disease course and haven’t experienced
repeated relapses may be more willing to take risks in order to assess their ability to
remain well without medication.9
The influence of gender in adherence is highly controversial. While some studies
report female gender as a negative determinant of adherence,23 12
others found no
9 25
association. In an homeless French population, female gender was found to be a risk
factor for non-adherence mostly due to increased reported side-effects and increased
negative attitudes towards medication.12 Women seem to experience more negative
side-effects probably due to biological differences impacting drug metabolism,
particularly because antipsychotics are mostly tested in middle-aged men to avoid the
concerns with pregnancy.12
Non-adherent patients are more likely to live alone than adherent patients, which
may mirror an inadequate support by relatives and caregivers.18
Full adherent patients have been shown to have a higher body mass index (BMI)
in comparison to those with partial adherence.7 30
Overweight patients are unlikely to
gain extra weight during treatment and/or are more likely to accept this medication’s side-
effect.7 30 Although this is a plausible explanation, others have attributed this association
to naturalistic study designs, where patients who comply with medication over time are
more likely to gain weight.7 On the other hand, a strong correlation has also been
reported between a higher BMI and non-adherence, which can be due to the distress
caused by weight gain.35
The influence of employment and educational status in compliance with treatment
has also been studied.18 23 31
Illiterate schizophrenic patients were found to be
significantly less adherent to medication.31 In the same way, being employed full-time or
8
having a significant higher educational level (of 13 or more years) was shown to improve
adherence.23 18 Patients who are employed and have a higher educational level appear
to have a higher level of insight and functioning, which may contribute to improved
adherence.18 However, a higher educational level has also been associated with worse
compliance,3 possibly due to other intervening variables such as negative attitudes
toward medication.3
3.2.2. Adherence background
Previous non-adherence to medication is also an important factor impacting

future compliance.30 A study has found that non-adherence in the 4 weeks prior to the
start of a new medication was the strongest predictor of subsequent non-adherence.30
Moreover, patients starting antipsychotics were more frequently non-adherent than those
with previous consistent use of the same drugs, implying that patients need time to adjust
and become adherent to an antipsychotic.32 8
3.2.3. Alcohol and drug use
Past or current alcohol and drug use is common amongst schizophrenic patients
and most studies have considered these risk factors for medication non-adherence.9 30
15 33
Patients with addictions are, in many cases, primarily concerned with short-term
demands, investing less on long-term goals, including those related to their own health.
Furthermore, these patients often exhibit psychiatric comorbidities and are commonly
stigmatized within medical environments, generating mistrust and fueling avoidance of
the system.36 There is still debate, however, on whether substance abuse is a cause or
a consequence of non-adherence.28 To better answer this question, detailed prospective
studies will be needed.28
3.2.4. Social functioning
In the context of schizophrenia, being socially active relates to better adherence

to treatment.30 This is thought to be mediated by the severity of patients’ positive
symptoms, which highly impact their social skills.30 A good psychosocial function,
especially in the areas of self-care and social networks, was also shown to be one of the
two best predictors of compliance.19 The engagement in activities such as art therapy,
social skills training and cognitive behavioral therapy also had a positive impact on
adherence.18
9
3.2.5. Religion
Religion can provide support for patients whose social life and individual identity
has been hindered by the disease, fostering feelings of hope and purpose.6 However,
religious beliefs can also lead to the replacement or delay of medical treatment, since
some groups focus solely on spiritual healing and perceive suffering as salutary.6
Christianity was found to be a predictive factor of adherence.4 Christian patients
were found to be 3,23 times more likely to commit to treatment than Buddhists, Muslims,
Hindus and free thinkers.4 Authors attribute this to the fact that Christians tend to be less
stigmatized by their religious peers,4 and that Christianity is more receptive to science-
based and less supportive of superstition-based treatments.4
In a study conducted in the United Arab Emirates, the involvement of patients
with faith healers was significantly associated with non-adherence,27 and
recommendations were made to educate patients and families on the consequences of
such practices.27
3.2.6. Attitudes toward medication
It is known that the patient’s attitudes toward medication may not translate directly
into behaviors of adherence and non-adherence.20 A patient may forget to take the
medication even though he understands its benefits.20 The same happens with someone
who, although believing the medication is unnatural, harmful, lenghty or unnecessary,
takes it for other reasons, such as pressure from others.20
Other studies have reached different results, with a negative attitude towards
medication predicting non-adherence directly.19 31 These patients have also been shown
to have lower levels of insight, more medication side-effects and diminished trust in the
doctor-patient relationship.37 11
It seems that several variables are able to change the
patient’s view and attitude towards the treatment, ultimately impacting adherence.
Concerning patients exhibiting positive attitudes, 85% were adherent to
medication,20 and this pattern has been found in independent studies.11 31 18
10
3.3. Environmental-related factors
3.3.1. Living area
Improved medication adherence has been observed in schizophrenic patients

living in a non-metropolitan area.8 In rural areas patients are thought to have a stronger
social support network and a closer relationship with their physician, as well as less
assess to illicit drugs, all factors associated with improved adherence.8
3.3.2. Poverty
In a study conducted in rural Ethiopia, the most common reason for non-
adherence among schizophrenic patients was the lack of assess to basic livelihood, such
as proper food.38 Moreover, in empoverished areas which commonly lack community
mental health care, the support from family members is even more important since it is
often the only one in which the patient can rely.38
In the homeless population, the estimated prevalence of schizophrenia is
approximately 11%.12 Considering the unique difficulties and context of this population,
it is understandable that, to these patients, medication adherence is not a primary
concern. Pharmacological and non-pharmacological strategies should, in this way, be
laid out to better address schizophrenia in the context of homelessness.12
3.3.3. Stigma and support from others
Because of the low mental health literacy among the general population, people
tend to distance themselves from those exhibiting strange behaviour.4 Schizophrenic
patients fear being labeled as mentally ill, since this is frequently associated with fewer
marriage and job opportunities.38 Stigma is, thus, a powerful barrier to adherence.38
On the other hand, patients feel safe and understood sharing their condition with
a significant other who provides support and encouragement.4 19 A caregiver is of great
importance to these patients as it was found by a study that 44% of adherent patients
had a family caregiver, contrasting with only 24,6% of non-adherent patients.18 However,
significant others can also negatively impact adherence,21 as it was noted in a sample of
72 non-adherent patients, in which 20% attributed non-compliance to friends or family
advice against medication intake.21
11
3.3.4. Doctor-patient relationship
Patients who place trust in their doctor and report good relationships with medical
personnel exhibit better medication adherence.4 11
Likewise, when the psychiatrist
includes the patient in the medication decision process, he tends to feel better informed
and more open to discuss fears and uncertainties.39 An important thing to consider is the
confounding effect of insight in the association between the quality of the therapeutic
relationship and adherence.39 The extent to which the patient perceives the relationship
as satisfactory depends on the concordance between doctor’s and patient’s views and
goals, which is naturally increased when the patient has preserved insight.39
3.4. Hospitalizations and medication-related factors
3.4.1. Hospitalizations
Non-adherence is more frequent in patients with multiple past and short-duration

hospitalizations and who required hospitalization at the onset of the disease. 8 18 20 30
Patients who are hospitalized at the onset of illness presumably exhibit more
severe symptomology and that could itself explain the trend to non-adhere.20
Apart from the number of previous hospitalizations which also predicted non-
adherence,18 30 one study showed that patients with an hospitalization of over two weeks
of duration were more likely to be adherent after discharge in comparison to patients with
shorter hospitalizations.8 The latter, who more frequently self-discharge, may do so
owing to a poor therapeutic alliance.8 On the other hand, longer hospitalizations enable
a stronger therapeutic alliance to be established and allows time for a better decision to
be made in relation to the medication discharge plan.8
3.4.2. Medication side-effects
Side-effects from medication are often referred as the most important contributor
to non-adherence, 21 22 although other studies don’t find such association.7 A patient who
had previous negative experiences with medication, either through distressful side-
effects or non-response, is likely to feel skeptical about it.39 Moreover, the weight of
specific side-effects will depend upon study population.22
In general, side-effects strongly associated with non-adherence vary widely
between studies and include extrapyramidal symptoms, such as tardive dyskinesia,
akathisia and parkinsonism, cognitive side-effects such as sedation, sleepiness and
12
dizziness, autonomic side-effects such as diarrhea and nausea and diminished sexual
drive and weight gain.3 7 22
Another point worth noting is the difference between acutely ill and stable patients
on chronic treatment. Acutely ill patients, in which lack of insight and delusions
predominate, are likely to overestimate the improvement in positive symptoms,
underestimating side-effects from medication.16 On the other hand, multiepisode
schizophrenic patients report changes in appearance as a significant reason for non-
adherence, in comparison to first episode patients.40 It is important to take into account
that long term users of antipsychotics may underreport side-effects both because they
get used to them or believe the side-effects are deeply intertwined with the benefits of
treatment.18
The balance between the discomfort from side-effects and the medication’s
benefits seems more relevant in terms of adherence than side-effects alone.18
3.4.3. First- and second-generation antipsychotics
The impact of the type of antipsychotic on adherence has been a matter of debate
and also of controversy since studies differ widely.10 While some don’t find a relationship
between the type of antipsychotic used and the level of medication adherence,11 33 19
adherence was reported to be significantly higher when using typical antipsychotics,23

although the same was found in relation to atypical antipsychotics.18 15
In clinical practice, although metabolic side-effects and weight gain, potential
threats to adherence, are more commonly attributed to atypical antipsychotics, these
seem to have supplanted the real concern with extrapyramidal side-effects more
frequently caused by typical antipsychotics.28 However, some authors don’t see this so
starkly, attributing equal importance to adverse effects arising from both types of
antipsychotics.3
3.4.4. Oral and long-acting injectable (LAI) antipsychotics
One of the aims in the development of LAI antipsychotics, also known as depot
antipsychotics, was improving adherence in schizophrenia.41 These new drugs would
also allow earlier and easier detection of relapse, clearer distinction between lack of
adherence and lack of efficacy, reduced risk of self-poisoning and more stable and
predictable serum concentrations.41 In face of non-adherence, LAI antipsychotics also
would have the advantage of creating a window of opportunity to encourage patient’s
compliance without a precipitous drop in drug levels.42
13
The use of LAI antipsychotics in the treatment of schizophrenia has then been
proposed as an alternative to their oral counterparts when there is a concern of poor
adherence but in real-life discontinuation still occurs, albeit in a smaller percentage
comparing to oral antipsychotics.41 43
However, this benefit on adherence is not
supported by all studies.18
One could hypothesize that LAI antipsychotics would improve adherence mainly
through improved efficacy. In terms of such claim, debate on whether the clinical
outcomes are improved by their use over oral antipsychotics is still ongoing.41 43 A large
randomized control trial concluded LAI antipsychotics were not superior to oral
antipsychotics in terms of time to hospitalization, symptom relief and quality of life.44 On
the contrary, they have shown to reduce hospitalization frequency in a meta-analysis of
mirror-image studies.45
In the clinical setting, LAI antipsychotics still tend to have low prescribing rates,
mostly ascribed to psychiatrists’ concerns.41 These include the potentially stigmatizing
effect of such drugs, concerns about the loss of patient’s autonomy, beliefs that they are
associated with worse side-effects in comparison to their oral counterparts and concerns
related to patient’s acceptance.41 The cost of LAI antipsychotics has also been pointed
as a reason for underprescription, since this drug’s availability is often restricted in certain
areas by the institutions holding the medication budget.41
Although most evidence seems to support the use of LAI antipsychotics to the
benefit of adherence,2 it remains questionable whether depot antipsychotics truly
improve adherence or simply reveal non-adherence in patients with schizophrenia.
3.4.5. Medication scheme
It has been found that a complex regimen comprised of many medications with a
high frequency of administration negatively affects adherence.26 This is especially
pertinent in schizophrenia, since the cognitive deficits associated with the disease further
impact the ability to understand an already complex regimen.26
However, it has been found that patients taking both types of antipsychotics,
instead of just one, more likely remembered to take the medication.4 Authors propose
that, in these patients, one antipsychotic is not enough for symptom improvement, hence
patients taking more than one showed better compliance.4 The same probably applies
to patients on other psychiatric medications such as mood stabilizers, anticonvulsants,
anticholinergics and anxiolytics.32
14
3.5. First episode psychosis (FEP) and multiepisode schizophrenia
First episode and multiepisode schizophrenia patients seem to have different

motivations to adhere to antipsychotic therapy.40
FEP patients are peculiar in the way that their short disease course hasn’t allowed
them the time to reach a “cause and effect” conclusion about medication. Unable to
perceive symptom relief deriving from antipsychotics, they are prone to deem medication
unnecessary once free from symptoms.40 However, other authors have found opposite
results, with FEP patients whose positive symptoms were relieved by medication being
more likely to stay adherent.46 These patients consider the doctor-patient relationship as
the most relevant factor driving adherence.40 Hence, in the first-episode crisis, it is
essential to create a strong therapeutic alliance, within which patient’s beliefs, life goals
and insight into illness are taken into account.40
Multiepisode patients have different motivations, including the desire to prevent
relapse and the understanding of the treatment’s benefits.40 Non-adherence in this group
is highly related to changes in appearance due to medication, since their longer
treatment course allows these effects to stand out.40
The moment in which the first episode occurs is also relevant for compliance.20
In adolescent FEP patients it was found that a decreased symptom burden was
predictive of non-adherence, which may seem counterintuitive.20 47 However, in this age
group, the tighter parental supervision leads to greater adherence if symptomology is
severe.20 On the other hand, adult FEP patients are less likely to be supervised, and their
adherence more closely impacted by symptom severity.47
3.6. Persistent refusal
While most non-adherent patients may be partially non-adherent, there is an

understudied group which consistently denies medication, over a long period of time.39
Persistent refusers, when compared to fully adherent patients, were found to
have lower insight levels and more frequently considered previous medications unhelpful
and previous psychiatrists unsatisfactory.39 Moreover, they felt they had been less
informed about medication in the past.39
Although this group of patients was thought to be more severely impaired and
thus less able to make judicious decisions, they were also found to have been through
relatively long periods of medication in the past, making it likely that the decision to refuse
had been rational and deliberate.39
15
4. Discussion
Adherence is a complex topic mainly because benefits and disadvantages of

pharmacological treatment vary between patients, according to different sets of goals,
beliefs and circumstances.26 Thus, a personalized and dynamic approach is needed.26
Although many factors have been shown to predict non-adherence, and
strategies aimed at correcting them are likely to retrieve positive results, there is a set of
patients in which medication intake is the only way to improve adherence on the short
and long-term. This includes decompensated patients with intense positive
symptomology, low insight, disorganized thoughts and dysfunctional behavior.
The establishment of a therapeutic alliance seems of upmost importance and
likely paves the way to address multiple non-adherence risk factors. There is a need for
longer consultations within a caring environment, in which there can be an assessment
of patients’ concerns, beliefs, positive and negative attitudes, symptomology, cognitive
ability, social functioning and family support.26 Providers should be clear, simple,
instructive and encourage patients to ask questions and be a part of the decision-making
process. Treatment should be tailored to patients’ hopes and expectations,26 taking into
account their economic resources.13 This should also prevent the search for alternative
treatments unsupported by scientific evidence.38
Besides a good therapeutic alliance, the involvement of family members or other
caregivers seems crucial, since these can better monitor and motivate the patient to
follow treatment.22 For those with strong negative attitudes, psychotherapy and
psychoeducation might be of particular importance, by challenging dysfunctional beliefs
both about the disorder and its treatment.21 For patients who feel ambivalent towards the
psychotic experience, cognitive behavioral therapy may help counter delusional
assumptions without invalidating the experience of the patient.21
Side-effects from medication should be searched for in every appointment and
medication switched if necessary. Drug and alcohol use should be prevented or reduced.
Although the association between cognitive dysfunction in schizophrenia and
poor adherence is uncertain, consensus guidelines indicate that it is a factor contributing
to non-adherence.48 For patients in which memory impairment is an important factor,22
the use of memory aids, such as alarms, calendars, behavior prompts associated with
everyday tasks and notes in visible places, may be a way of improving adherence.26
These patients could also benefit from LAI antipsychotics, that assure medication
delivery.22 Cognitive behavioral therapy integrating cognitive remediation has also been
proposed to surpass this barrier.14 48
Despite the controversy surrounding the impact of LAI antipsychotics on
adherence, these tend to be used to improve adherence in high risk individuals in clinical
practice, their higher cost being offset by less hospitalization costs on the long term.2 45
16
Both atypical and typical antipsychotics seem to yield similar efficacy in
schizophrenia’s symptoms and relapse risk.2 10 In this way, the choice of antipsychotic is
normally guided by side-effects or patient’s specific factors, such as comorbidities and
past experience with these drugs.2 Although there is conflicting evidence regarding which
type of antipsychotic is better in terms of adherence, most clinicians favor the use of
atypical antipsychotics, which are less likely to induce prominent extrapyramidal
symptoms and endocrinal side-effects.10
Simplifying the treatment regimen, both in terms of amount of medication and
frequency of administration, is a way of improving adherence. Depot antipsychotics are
also an effective way of simplifying the regimen while guaranteeing administration.26
The inconsistent results often found can be ascribed to several limitations unique
to adherence studies. In the first place, the definition of medication adherence varies
widely between studies10 and there are no universally established cut-off points. As
adherence can be evaluated in categorical, dichotomous and continuous ways,10 there
should be an effort to standardize its measurement and categorization.26
Moreover, medication adherence can be generally assessed in two ways:
objetively and subjetively.10 Objetive assessments, such as the measurement of urine or
serum antipsychotic concentrations, seem more reliable and take into account individual
pharmacokinetics, but are usually limited by financial constraints.8 10
Other examples
include the direct observation of medication intake, pill counts, electronic monitoring
systems (MEM) and pharmacy refill records.10 Subjective assessments are the most
commonly used in research, mostly because of their time and cost effectiveness, ease
of use and relative reliability.15 These include patient’s self-report, interviews, diaries or
provider reports.8 49
Although self-reporting questionnaires are patient-friendly, less
expensive and easier to conduct,23 they rely on patient recall, and overestimation is likely
to occur.10 9 It has been proposed that studies should include two measurements in their
adherence assessment where at least one is objetive.7
Most studies are also designed as cross-sectional.8 Limitations include failure to
assess patients over time, limiting cause-effect conclusions,31 especially since
adherence is a dynamic process.18
Adherence is a complex topic in schizophrenia, with current literature exhibiting
vast and heterogenous findings. Since the biology of the disease is itself an intervening
factor and variables strongly interplay with one another, it is often difficult to establish
predictive relations.
Taking into account the importance of this topic, and since patients’ behavior is
known to fluctuate over time, future research should focus on prospective study designs
over long periods of time, and in large samples, under naturalistic settings.
17
Acknowledgements
Not applicable.
Funding
This research did not receive any specific grant from funding agencies in the public,
commercial, or not-for-profit sectors.
Declaration of interest
None.
18
References
1. American Psychiatry Association Apa. DSM-V-TR - Manual Diagnóstico e Estatístico de

Transtornos Mentais.; 2013. doi:1011769780890425596
2. Brugnoli R, Rapinesi C, Kotzalidis GD, et al. Model of Management (Mo.Ma) for the patient
with schizophrenia: Crisis control, maintenance, relapse prevention, and recovery with long-
acting injectable antipsychotics (LAIs). Riv Psichiatr. 2016.
3. DiBonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E. A patient perspective of the impact
of medication side effects on adherence: Results of a cross-sectional nationwide survey of
patients with schizophrenia. BMC Psychiatry. 2012. doi:10.1186/1471-244X-12-20
4. Tham XC, Xie H, Chng CML, Seah XY, Lopez V, Klainin-Yobas P. Exploring predictors of
medication adherence among inpatients with schizophrenia in Singapore’s mental health
settings: A non-experimental study. Arch Psychiatr Nurs. 2018. doi:10.1016/j.apnu.2018.
02.004
5. Zhou Y, Rosenheck R, Mohamed S, Ning Y, He H. Factors associated with complete
discontinuation of medication among patients with schizophrenia in the year after hospital
discharge. Psychiatry Res. 2017. doi:10.1016/j.psychres.2017.01.036
6. Borras L, Mohr S, Brandt PY, Gilliéron C, Eytan A, Huguelet P. Religious beliefs in
schizophrenia: Their relevance for adherence to treatment. Schizophr Bull. 2007.
doi:10.1093/schbul/sbl070
7. Jónsdóttir H, Opjordsmoen S, Birkenaes AB, et al. Predictors of medication adherence in
patients with schizophrenia and bipolar disorder. Acta Psychiatr Scand. 2012.
doi:10.1111/j.1600-0447.2012.01911.x
8. Reutfors J, Brandt L, Stephansson O, Kieler H, Andersen M, Bodén R. Antipsychotic
prescription filling in patients with schizophrenia or schizoaffective disorder. J Clin
Psychopharmacol. 2013. doi:10.1097/JCP.0b013e3182a1cd2e
9. Alene M, Wiese MD, Angamo MT, Bajorek B V., Yesuf EA, Wabe NT. Adherence to
medication for the treatment of psychosis: rates and risk factors in an Ethiopian population.
BMC Clin Pharmacol. 2012. doi:10.1186/1472-6904-12-10
10. Sendt KV, Tracy DK, Bhattacharyya S. A systematic review of factors influencing adherence
to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Res. 2015.
doi:10.1016/j.psychres.2014.11.002
11. Baloush-Kleinman V, Levine SZ, Roe D, Shnitt D, Weizman A, Poyurovsky M. Adherence to
antipsychotic drug treatment in early-episode schizophrenia: A six-month naturalistic follow-
up study. Schizophr Res. 2011. doi:10.1016/j.schres.2011.04.030
12. Tinland A, Zemmour K, Auquier P, et al. Homeless women with schizophrenia reported lower
adherence to their medication than men: results from the French Housing First experience.
Soc Psychiatry Psychiatr Epidemiol. 2017. doi:10.1007/s00127-017-1411-z
13. Wade M, Tai S, Awenat Y, Haddock G. A systematic review of service-user reasons for
adherence and nonadherence to neuroleptic medication in psychosis. Clin Psychol Rev.
2017. doi:10.1016/j.cpr.2016.10.009
14. El-Missiry A, Elbatrawy A, El Missiry M, Moneim DA, Ali R, Essawy H. Comparing cognitive
functions in medication adherent and non-adherent patients with schizophrenia. J Psychiatr
Res. 2015. doi:10.1016/j.jpsychires.2015.09.006
15. Iasevoli F, Fagiolini A, Formato MV, et al. Assessing patient-rated vs. clinician-rated
adherence to the therapy in treatment resistant schizophrenia, schizophrenia responders,
and non-schizophrenia patients. Psychiatry Res. 2017. doi:10.1016/j.psychres.2017.01.015
16. Ascher-Svanum H, Nyhuis AW, Stauffer V, et al. Reasons for discontinuation and
continuation of antipsychotics in the treatment of schizophrenia from patient and clinician
perspectives. Curr Med Res Opin. 2010. doi:10.1185/03007995.2010.515900
17. Liu-Seifert H, Osuntokun OO, Feldman PD. Factors associated with adherence to treatment
with olanzapine and other atypical antipsychotic medications in patients with schizophrenia.
Compr Psychiatry. 2012. doi:10.1016/j.comppsych.2010.12.003
18. Vassileva I, Milanova V, Asan T. Predictors of Medication Non-adherence in Bulgarian
Outpatients with Schizophrenia. Community Ment Health J. 2014. doi:10.1007/s10597-014-
9697-8
19. Brain C, Allerby K, Sameby B, et al. Drug attitude and other predictors of medication
adherence in schizophrenia: 12 months of electronic monitoring (MEMS®) in the Swedish
COAST-study. Eur Neuropsychopharmacol. 2013. doi:10.1016/j.euroneuro.2013.09.001
19
20. Hui CLM, Poon VWY, Ko WT, et al. Risk factors for antipsychotic medication non-adherence
behaviors and attitudes in adult-onset psychosis. Schizophr Res. 2016.
doi:10.1016/j.schres.2016.03.026
21. Moritz S, Favrod J, Andreou C, et al. Beyond the usual suspects: Positive attitudes towards
positive symptoms is associated with medication noncompliance in psychosis. Schizophr
Bull. 2013. doi:10.1093/schbul/sbs005
22. Moritz S, Hünsche A, Lincoln TM. Nonadherence to antipsychotics: The role of positive
attitudes towards positive symptoms. Eur Neuropsychopharmacol. 2014.
doi:10.1016/j.euroneuro.2014.09.008
23. Stentzel U, van den Berg N, Schulze LN, et al. Predictors of medication adherence among
patients with severe psychiatric disorders: Findings from the baseline assessment of a
randomized controlled trial (Tecla). BMC Psychiatry. 2018. doi:10.1186/s12888-018-1737-4
24. Barnett JH, Salmond CH, Jones PB, Sahakian BJ. Cognitive reserve in neuropsychiatry.
Psychol Med. 2006. doi:10.1017/S0033291706007501
25. Bitter I, Fehér L, Tényi T, Czobor P. Treatment adherence and insight in schizophrenia.
Psychiatr Hung. 2015.
26. Hardeman SM, Harding RK, Narasimhan M. Simplifying adherence in schizophrenia.
Psychiatr Serv. 2010. doi:10.1176/ps.2010.61.4.405
27. Abdel Aziz K, Elamin MH, El-Saadouni NM, et al. Schizophrenia: Impact of psychopathology,
faith healers and psycho-education on adherence to medications. Int J Soc Psychiatry. 2016.
doi:10.1177/0020764016676215
28. Czobor P, Van Dorn RA, Citrome L, Kahn RS, Fleischhacker WW, Volavka J. Treatment
adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST
studies. Eur Neuropsychopharmacol. 2015. doi:10.1016/j.euroneuro.2015.04.003
29. Czobor P, Volavka J, Derks EM, et al. Insight and hostility as predictors and correlates of
nonadherence in the European first episode schizophrenia trial. J Clin Psychopharmacol.
2013. doi:10.1097/JCP.0b013e3182856886
30. Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. Predictors and clinical
consequences of non-adherence with antipsychotic medication in the outpatient treatment
of schizophrenia. Psychiatry Res. 2010. doi:10.1016/j.psychres.2009.05.004
31. Eticha T, Teklu A, Ali D, Solomon G, Alemayehu A. Factors associated with medication
adherence among patients with schizophrenia in Mekelle, Northern Ethiopia. PLoS One.
2015. doi:10.1371/journal.pone.0120560
32. Lang K, Federico V, Muser E, Menzin J, Menzin J. Rates and predictors of antipsychotic
non-adherence and hospitalization in Medicaid and commercially-insured patients with
schizophrenia. J Med Econ. 2013. doi:10.3111/13696998.2013.816310
33. Lang K, Meyers JL, Korn JR, et al. Medication adherence and hospitalization among patients
with schizophrenia treated with antipsychotics. Psychiatr Serv. 2010.
doi:10.1176/ps.2010.61.12.1239
34. Ritchie CW, Harrigan S, Mastwyk M, Macfarlane S, Cheesman N, Ames D. Predictors of
adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with
schizophrenia: An open study of 31/2 years duration. Int J Geriatr Psychiatry. 2010.
doi:10.1002/gps.2354
35. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic
noncompliance. Schizophr Res. 2004. doi:10.1016/S0920-9964(02)00498-X
36. Lucas GM. Substance abuse, adherence with antiretroviral therapy, and clinical outcomes
among HIV-infected individuals. Life Sci. 2011. doi:10.1016/j.lfs.2010.09.025
37. Samalin L, de Chazeron I, Blanc O, Brunel L, Fond G, Llorca PM. Attitudes toward
antipsychotic medications as a useful feature in exploring medication non-adherence in
schizophrenia. Schizophr Res. 2016. doi:10.1016/j.schres.2016.09.015
38. Teferra S, Hanlon C, Beyero T, Jacobsson L, Shibre T. Perspectives on reasons for non-
adherence to medication in persons with schizophrenia in Ethiopia: A qualitative study of
patients, caregivers and health workers. BMC Psychiatry. 2013. doi:10.1186/1471-244X-13-
168
39. Lincoln TM, Jung E, Wiesjahn M, Wendt H, Bock T, Schlier B. The impact of negative
treatment experiences on persistent refusal of antipsychotics. Compr Psychiatry. 2016.
doi:10.1016/j.comppsych.2016.07.009
40. Sapra M, Weiden PJ, Schooler NR, Sunakawa-McMillan A, Uzenoff S, Burkholder P.
Reasons for adherence and nonadherence: A pilot study comparing first-and multi-episode
schizophrenia patients. Clin Schizophr Relat Psychoses. 2014.
20
doi:10.3371/CSRP.SAWE.020813
41. Patel MX, Taylor M, David AS. Antipsychotic long-acting injections: Mind the gap. Br J
Psychiatry. 2009. doi:10.1192/bjp.195.52.s1
42. Nielsen J, Jensen SOW, Friis RB, Valentin JB, Correll CU. Comparative effectiveness of
risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in
schizophrenia: Results from a nationwide, retrospective inception cohort study. Schizophr
Bull. 2015. doi:10.1093/schbul/sbu128
43. Verdoux H, Pambrun E, Tournier M, Bezin J, Pariente A. Risk of discontinuation of
antipsychotic long-acting injections vs. oral antipsychotics in real-life prescribing practice: a
community-based study. Acta Psychiatr Scand. 2017. doi:10.1111/acps.12722
44. Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in
unstable schizophrenia. N Engl J Med. 2011. doi:10.1056/NEJMoa1005987
45. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable versus oral
antipsychotics in schizophrenia: A systematic review and meta-analysis of mirror-image
studies. J Clin Psychiatry. 2013. doi:10.4088/JCP.13r08440
46. Mustafa S, Joober R, Lepage M, Iyer S, Shah J, Malla A. Predictors of ‘all-cause
discontinuation’ of initial oral antipsychotic medication in first episode psychosis. Schizophr
Res. 2018. doi:10.1016/j.schres.2018.04.027
47. Lai-Ming Hui C, Wing-Yan Poon V, Shuk-Kuen Kwok V, et al. Prevalence and predictors of
medication non-adherence among Chinese patients with first-episode psychosis. Psychiatry
Res. 2015. doi:10.1016/j.psychres.2015.04.047
48. Keefe RSE, Haig GM, Marder SR, et al. Report on ISCTM Consensus Meeting on Clinical
Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia. Schizophr
Bull. 2016. doi:10.1093/schbul/sbv111
49. Jaeger S, Pfiffner C, Weiser P, et al. Adherence styles of schizophrenia patients identified
by a latent class analysis of the Medication Adherence Rating Scale (MARS): A six-month
follow-up study. Psychiatry Res. 2012. doi:10.1016/j.psychres.2012.03.033
21
Agradecimentos
Ao Sr. Prof. Doutor Manuel Esteves pela orientação, disponibilidade e dedicação na

realização deste trabalho, bem como por partilhar comigo o seu conhecimento e espírito
criativo.
Aos meus pais, por tudo.
Aos meus amigos, pelo ânimo que me deram nos momentos certos.
Obrigada.
22
ANEXOS
Normas da revista: Comprehensive Psychiatry
23
COMPREHENSIVE PSYCHIATRY
AUTHOR INFORMATION PACK
TABLE OF CONTENTS XXX

. .
• Description p.1
• Impact Factor p.1
• Abstracting and Indexing p.1
• Editorial Board p.1
• Guide for Authors p.3
ISSN: 0010-440X
DESCRIPTION
.
Comprehensive Psychiatry is an open access, peer-reviewed journal that publishes on all aspects of
psychiatry and mental health. The mission of this journal is to disseminate cutting edge knowledge in
order to improve patient care and advance the understanding of mental illness. With the support of an
expanded international team of editors and peer reviewers, we aim to publish high quality papers with
a particular emphasis on the clinical implications of the work including the improved understanding
of psychopathology. We encourage our authors to adopt an accessible approach to presenting their
findings, to promote the fullest engagement with clinicians and other interested parties. Through our
new open access policy, we expect our papers will deliver the widest global impact, opening up fruitful
scientific engagement with researchers outside the immediate circle, as well as with mental health
clinicians, interested policy-makers and the public.
IMPACT FACTOR
.
2018: 2.586 © Clarivate Analytics Journal Citation Reports 2019
ABSTRACTING AND INDEXING

.
PubMed Central
Web of Science
Scopus
Directory of Open Access Journals (DOAJ)
EDITORIAL BOARD
.
Editor-in-Chief
N. Fineberg, University of Hertfordshire, Hatfield, United Kingdom
Associate Editor
S. Chamberlain, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
E. Grünblatt, Psychiatric University Hospital Zurich, Zurich, Switzerland
R. Li, Capital University of Medical Sciences, Beijing, China
F. Schneier, Columbia University Irving Medical Center, New York, New York, United States
AUTHOR INFORMATION PACK 7 Feb 2020 www.elsevier.com/locate/comppsych 1

Editorial Office
Editors Emeriti
D.L. Dunner, Mercer Island, WA, USA
J.C. Markowitz, New York State Psychiatric Institute, New York, New York, United States
R.A. O'Connell
Editorial Board
M. van Ameringen, McMaster University, Hamilton, Ontario, Canada
B. Boland, Hertfordshire Partnership University NHS Foundation Trust, St Albans, United Kingdom
C.R. Cloninger, Washington University in Saint Louis School of Medicine, Saint Louis, Missouri, United States
W.H. Coryell, University of Iowa, Iowa City, Iowa, United States
J.R. DePaulo, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
B.M. Dell'Osso, University of Milan, Milano, Italy
J. Du, Shanghai Mental Health Center Drug Abuse Treatment Center, Shanghai, China
E. Fernandez-Egea, University of Cambridge, Cambridge, United Kingdom
L.F. Fontenelle, Monash University, Clayton, Victoria, Australia
D.A. Geller, Massachusetts General Hospital - Harvard Medical School Center for Nervous System Repair, Boston,
Massachusetts, United States
J. E. Grant, University of Chicago, Chicago, Illinois, United States
G. Grassi
E. Hollander, Yeshiva University Albert Einstein College of Medicine, Bronx, New York, United States
K. Ioannidis, University of Cambridge, Cambridge, United Kingdom
S. Kasper, University of Vienna, Wien, Austria
K.R. Laws, University of Hertfordshire, Hatfield, United Kingdom
B. Lerer, Hadassah Medical Center, Jerusalem, Israel
M. Mohler-Kuo
S.A. Montgomery, Imperial College London, London, United Kingdom
S. Morein
Z. Nemoda, Semmelweis University of Medicine, Budapest, Hungary
A. Ozerdem, Dokuz Eylül University, İzmir, Turkey
S. Pallanti, Stanford University Department of Psychiatry and Behavioral Sciences, Palo Alto, California, United
States
K. A. Phillips, Cornell University, New York, New York, USA
A. J. Rothschild, University of Massachusetts Medical School, Worcester, Massachusetts, United States
N. Sartorius, Association for the Improvement of Mental Health Programmes, Geneva, Switzerland
L. J. Siever, Icahn School of Medicine at Mount Sinai, New York, New York, United States
D. J. Stein, University of Cape Town Department of Psychiatry and Mental Health, Cape Town, South Africa
J. Stochl, University of Cambridge, Cambridge, United Kingdom
M. Zimmerman, Rhode Island Hospital, Providence, Rhode Island, United States

GUIDE FOR AUTHORS
.
INTRODUCTION
From January 2019 Comprehensive Psychiatry will move from a subscription to a gold open access
publishing model. Authors who publish in Comprehensive Psychiatry will make their work immediately,
st
permanently, and freely accessible. Authors submitting to the journal on or after 31 October 2018
will be expected to cover the cost of the Article Publishing Charge (APC) to publish in the journal, will
have a choice of license options and will retain copyright to their published work.
Comprehensive Psychiatry is an open access, peer-reviewed journal that publishes on all aspects of
psychiatry and mental health. The mission of this journal is to disseminate cutting edge knowledge
in order to improve patient care and advance the understanding of mental illness.
Submission checklist
You can use this list to carry out a final check of your submission before you send it to the journal for
review. Please check the relevant section in this Guide for Authors for more details.
Ensure that the following items are present:
One author has been designated as the corresponding author with contact details:
• E-mail address
• Full postal address
All necessary files have been uploaded:

Manuscript:
• Include keywords
• All figures (include relevant captions)
• All tables (including titles, description, footnotes)
• Ensure all figure and table citations in the text match the files provided
• Indicate clearly if color should be used for any figures in print
Graphical Abstracts / Highlights files (where applicable)
Supplemental files (where applicable)
Further considerations
• Manuscript has been 'spell checked' and 'grammar checked'
• All references mentioned in the Reference List are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the
Internet)
• A competing interests statement is provided, even if the authors have no competing interests to
declare
• Journal policies detailed in this guide have been reviewed
• Referee suggestions and contact details provided, based on journal requirements
For further information, visit our Support Center.
BEFORE YOU BEGIN

Ethics in publishing
Please see our information pages on Ethics in publishing and Ethical guidelines for journal publication.
Declaration of interest
All authors must disclose any financial and personal relationships with other people or organizations
that could inappropriately influence (bias) their work. Examples of potential competing interests
include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent
applications/registrations, and grants or other funding. Authors must disclose any interests in two
places: 1. A summary declaration of interest statement in the title page file (if double-blind) or the
manuscript file (if single-blind). If there are no interests to declare then please state this: 'Declarations
of interest: none'. This summary statement will be ultimately published if the article is accepted.
2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the
journal's official records. It is important for potential interests to be declared in both places and that
the information matches. More information.

Submission declaration and verification
Submission of an article implies that the work described has not been published previously (except in
the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent
publication' for more information), that it is not under consideration for publication elsewhere, that
its publication is approved by all authors and tacitly or explicitly by the responsible authorities where
the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in
English or in any other language, including electronically without the written consent of the copyright-
holder. To verify originality, your article may be checked by the originality detection service Crossref
Similarity Check.
Preprints
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy.
Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple,
redundant or concurrent publication' for more information).
Use of inclusive language
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences,
and promotes equal opportunities. Articles should make no assumptions about the beliefs or
commitments of any reader, should contain nothing which might imply that one individual is superior
to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive
language throughout. Authors should ensure that writing is free from bias, for instance by using 'he
or she', 'his/her' instead of 'he' or 'his', and by making use of job titles that are free of stereotyping
(e.g. 'chairperson' instead of 'chairman' and 'flight attendant' instead of 'stewardess').
Changes to authorship
Authors are expected to consider carefully the list and order of authors before submitting their
manuscript and provide the definitive list of authors at the time of the original submission. Any
addition, deletion or rearrangement of author names in the authorship list should be made only
before the manuscript has been accepted and only if approved by the journal Editor. To request such
a change, the Editor must receive the following from the corresponding author: (a) the reason
for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they
agree with the addition, removal or rearrangement. In the case of addition or removal of authors,
this includes confirmation from the author being added or removed.
Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of
authors after the manuscript has been accepted. While the Editor considers the request, publication
of the manuscript will be suspended. If the manuscript has already been published in an online issue,
any requests approved by the Editor will result in a corrigendum.
Copyright
Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (see
more information on this). Permitted third party reuse of open access articles is determined by the
author's choice of user license.
Author rights
As an author you (or your employer or institution) have certain rights to reuse your work. More
information.
Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.
Role of the funding source
You are requested to identify who provided financial support for the conduct of the research and/or
preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in
the collection, analysis and interpretation of data; in the writing of the report; and in the decision to
submit the article for publication. If the funding source(s) had no such involvement then this should
be stated.
Open access
Please visit our Open Access page from the Journal Homepage for more information.

Elsevier Researcher Academy
Researcher Academy is a free e-learning platform designed to support early and mid-career
researchers throughout their research journey. The "Learn" environment at Researcher Academy
offers several interactive modules, webinars, downloadable guides and resources to guide you through
the process of writing for research and going through peer review. Feel free to use these free resources
to improve your submission and navigate the publication process with ease.
Language (usage and editing services)
Please write your text in good English (American or British usage is accepted, but not a mixture of
these). Authors who feel their English language manuscript may require editing to eliminate possible
grammatical or spelling errors and to conform to correct scientific English may wish to use the English
Language Editing service available from Elsevier's Author Services.
Informed consent and patient details
Studies on patients or volunteers require ethics committee approval and informed consent, which
should be documented in the paper. Appropriate consents, permissions and releases must be obtained
where an author wishes to include case details or other personal information or images of patients
and any other individuals in an Elsevier publication. Written consents must be retained by the author
but copies should not be provided to the journal. Only if specifically requested by the journal in
exceptional circumstances (for example if a legal issue arises) the author must provide copies of the
consents or evidence that such consents have been obtained. For more information, please review the
Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals. Unless
you have written permission from the patient (or, where applicable, the next of kin), the personal
details of any patient included in any part of the article and in any supplementary materials (including
all illustrations and videos) must be removed before submission.
Submission
Our online submission system guides you stepwise through the process of entering your article
details and uploading your files. The system converts your article files to a single PDF file used in
the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for
final publication. All correspondence, including notification of the Editor's decision and requests for
revision, is sent by e-mail.
Submit your article
Please submit your article via https://ees.elsevier.com/comprpsychiatry.
Referees
Please submit, with the manuscript, the names, addresses and e-mail addresses of six potential
referees. Recommended reviewers should be experts in the topic of your manuscript but not
immediately connected to you. Please do not recommend reviewers who might have a conflict of
interest: family members, immediate colleagues, prior co-authors or grant associates. The editor
retains the sole right to decide upon using suggested reviewers.
PREPARATION
Peer review
This journal operates a single blind review process. All contributions will be initially assessed by the
editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of
two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible
for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. More
information on types of peer review.
Use of word processing software
It is important that the file be saved in the native format of the word processor used. The text
should be in single-column format. Keep the layout of the text as simple as possible. Most formatting
codes will be removed and replaced on processing the article. In particular, do not use the word
processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts,
superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each
individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns.
The electronic text should be prepared in a way very similar to that of conventional manuscripts (see
also the Guide to Publishing with Elsevier). Note that source files of figures, tables and text graphics
will be required whether or not you embed your figures in the text. See also the section on Electronic
artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check'
functions of your word processor.
Article structure
Subdivision - numbered sections
Divide your article into clearly defined and numbered sections. Subsections should be numbered
1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this
numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be
given a brief heading. Each heading should appear on its own separate line.
Introduction
State the objectives of the work and provide an adequate background, avoiding a detailed literature
survey or a summary of the results.
Material and methods
Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods
that are already published should be summarized, and indicated by a reference. If quoting directly
from a previously published method, use quotation marks and also cite the source. Any modifications
to existing methods should also be described.
Results
Results should be clear and concise.
Discussion
This should explore the significance of the results of the work, not repeat them. A combined Results
and Discussion section is often appropriate. Avoid extensive citations and discussion of published
literature.
Conclusions
The main conclusions of the study may be presented in a short Conclusions section, which may stand
alone or form a subsection of a Discussion or Results and Discussion section.
Appendices
If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in
appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix,
Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.
Essential title page information
• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid
abbreviations and formulae where possible.
• Author names and affiliations. Please clearly indicate the given name(s) and family name(s)
of each author and check that all names are accurately spelled. You can add your name between
parentheses in your own script behind the English transliteration. Present the authors' affiliation
addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-
case superscript letter immediately after the author's name and in front of the appropriate address.
Provide the full postal address of each affiliation, including the country name and, if available, the
e-mail address of each author.
• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing
and publication, also post-publication. This responsibility includes answering any future queries about
Methodology and Materials. Ensure that the e-mail address is given and that contact details
are kept up to date by the corresponding author.
• Present/permanent address. If an author has moved since the work described in the article was
done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as
a footnote to that author's name. The address at which the author actually did the work must be
retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.
Highlights
Highlights are mandatory for this journal as they help increase the discoverability of your article via
search engines. They consist of a short collection of bullet points that capture the novel results of
your research as well as new methods that were used during the study (if any). Please have a look
at the examples here: example Highlights.
Highlights should be submitted in a separate editable file in the online submission system. Please
use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including
spaces, per bullet point).

Structured abstract
A structured abstract, by means of appropriate headings, should provide the context or background for
the research and should state its purpose, basic procedures (selection of study subjects or laboratory
animals, observational and analytical methods), main findings (giving specific effect sizes and their
statistical significance, if possible), and principal conclusions. It should emphasize new and important
aspects of the study or observations.
Graphical abstract
Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online
article. The graphical abstract should summarize the contents of the article in a concise, pictorial form
designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a
separate file in the online submission system. Image size: Please provide an image with a minimum
of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 ×
13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office
files. You can view Example Graphical Abstracts on our information site.
Authors can make use of Elsevier's Illustration Services to ensure the best presentation of their images
and in accordance with all technical requirements.
Keywords
Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and
avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing
with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords
will be used for indexing purposes.
Abbreviations
Define abbreviations that are not standard in this field in a footnote to be placed on the first page
of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first
mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.
Acknowledgements
Collate acknowledgements in a separate section at the end of the article before the references and do
not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those
individuals who provided help during the research (e.g., providing language help, writing assistance
or proof reading the article, etc.).
Formatting of funding sources
List funding sources in this standard way to facilitate compliance to funder's requirements:
Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy];
the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes
of Peace [grant number aaaa].
It is not necessary to include detailed descriptions on the program or type of grants and awards. When
funding is from a block grant or other resources available to a university, college, or other research
institution, submit the name of the institute or organization that provided the funding.
If no funding has been provided for the research, please include the following sentence:
This research did not receive any specific grant from funding agencies in the public, commercial, or
not-for-profit sectors.
Units
Follow internationally accepted rules and conventions: use the international system of units (SI). If
other units are mentioned, please give their equivalent in SI.
Math formulae
Please submit math equations as editable text and not as images. Present simple formulae in
line with normal text where possible and use the solidus (/) instead of a horizontal line for small
fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often
more conveniently denoted by exp. Number consecutively any equations that have to be displayed
separately from the text (if referred to explicitly in the text).

Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word
processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate
the position of footnotes in the text and list the footnotes themselves separately at the end of the
article. Do not include footnotes in the Reference list.
Artwork
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Embed the used fonts if the application provides that option.
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or
use fonts that look similar.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately.
• Size the illustrations close to the desired dimensions of the published version.
• Submit each illustration as a separate file.
• Ensure that color images are accessible to all, including those with impaired color vision.
A detailed guide on electronic artwork is available.

You are urged to visit this site; some excerpts from the detailed information are given here.
Formats
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then
please supply 'as is' in the native document format.
Regardless of the application used other than Microsoft Office, when your electronic artwork is
finalized, please 'Save as' or convert the images to one of the following formats (note the resolution
requirements for line drawings, halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings, embed all used fonts.
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of
500 dpi.
Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a
low number of pixels and limited set of colors;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.
Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or
MS Office files) and with the correct resolution. If, together with your accepted article, you submit
usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear
in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations
are reproduced in color in the printed version. For color reproduction in print, you will receive
information regarding the costs from Elsevier after receipt of your accepted article. Please
indicate your preference for color: in print or online only. Further information on the preparation of
electronic artwork.
Illustration services
Elsevier's Author Services offers Illustration Services to authors preparing to submit a manuscript but
concerned about the quality of the images accompanying their article. Elsevier's expert illustrators
can produce scientific, technical and medical-style images, as well as a full range of charts, tables
and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve
them to a professional standard. Please visit the website to find out more.
Figure captions
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A
caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep
text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the
relevant text in the article, or on separate page(s) at the end. Number tables consecutively in
accordance with their appearance in the text and place any table notes below the table body. Be
sparing in the use of tables and ensure that the data presented in them do not duplicate results
described elsewhere in the article. Please avoid using vertical rules and shading in table cells.
References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice
versa). Any references cited in the abstract must be given in full. Unpublished results and personal
communications are not recommended in the reference list, but may be mentioned in the text. If these
references are included in the reference list they should follow the standard reference style of the
journal and should include a substitution of the publication date with either 'Unpublished results' or
'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted
for publication.
Reference links
Increased discoverability of research and high quality peer review are ensured by online links to
the sources cited. In order to allow us to create links to abstracting and indexing services, such as
Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please
note that incorrect surnames, journal/book titles, publication year and pagination may prevent link
creation. When copying references, please be careful as they may already contain errors. Use of the
DOI is highly encouraged.
A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article.
An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M.,
James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath
northeastern Venezuela. Journal of Geophysical Research, https://doi.org/10.1029/2001JB000884.
Please note the format of such citations should be in the same style as all other references in the paper.
Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any
further information, if known (DOI, author names, dates, reference to a source publication, etc.),
should also be given. Web references can be listed separately (e.g., after the reference list) under a
different heading if desired, or can be included in the reference list.
Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them
in your text and including a data reference in your Reference List. Data references should include the
following elements: author name(s), dataset title, data repository, version (where available), year,
and global persistent identifier. Add [dataset] immediately before the reference so we can properly
identify it as a data reference. The [dataset] identifier will not appear in your published article.
References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in
the text) to other articles in the same Special Issue.
Reference management software
Most Elsevier journals have their reference template available in many of the most popular reference
management software products. These include all products that support Citation Style Language
styles, such as Mendeley. Using citation plug-ins from these products, authors only need to select
the appropriate journal template when preparing their article, after which citations and bibliographies
will be automatically formatted in the journal's style. If no template is yet available for this journal,
please follow the format of the sample references and citations as shown in this Guide. If you use
reference management software, please ensure that you remove all field codes before submitting
the electronic manuscript. More information on how to remove field codes from different reference
management software.
Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following
link:
http://open.mendeley.com/use-citation-style/comprehensive-psychiatry
When preparing your manuscript, you will then be able to select this style using the Mendeley plug-
ins for Microsoft Word or LibreOffice.

Reference style
Text: Indicate references by number(s) in square brackets in line with the text. The actual authors
can be referred to, but the reference number(s) must always be given.
List: Number the references (numbers in square brackets) in the list in the order in which they appear
in the text.
Examples:
Reference to a journal publication:
[1] Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. J Sci Commun
2010;163:51–9. https://doi.org/10.1016/j.Sc.2010.00372.
Reference to a journal publication with an article number:
[2] Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. Heliyon.
2018;19:e00205. https://doi.org/10.1016/j.heliyon.2018.e00205
Reference to a book:
[3] Strunk Jr W, White EB. The elements of style. 4th ed. New York: Longman; 2000.
Reference to a chapter in an edited book:
[4] Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith
RZ, editors. Introduction to the electronic age, New York: E-Publishing Inc; 2009, p. 281–304.
Reference to a website:
[5] Cancer Research UK. Cancer statistics reports for the UK, http://www.cancerresearchuk.org/
aboutcancer/statistics/cancerstatsreport/; 2003 [accessed 13 March 2003].
Reference to a dataset:
[dataset] [6] Oguro M, Imahiro S, Saito S, Nakashizuka T. Mortality data for Japanese oak wilt
disease and surrounding forest compositions, Mendeley Data, v1; 2015. https://doi.org/10.17632/
xwj98nb39r.1.
Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6
should be listed followed by 'et al.' For further details you are referred to 'Uniform Requirements for
Manuscripts submitted to Biomedical Journals' (J Am Med Assoc 1997;277:927–34) (see also Samples
of Formatted References).
Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations.
Supplementary material
Supplementary material such as applications, images and sound clips, can be published with your
article to enhance it. Submitted supplementary items are published exactly as they are received (Excel
or PowerPoint files will appear as such online). Please submit your material together with the article
and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to
supplementary material during any stage of the process, please make sure to provide an updated file.
Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option
in Microsoft Office files as these will appear in the published version.
Research data
This journal encourages and enables you to share data that supports your research publication
where appropriate, and enables you to interlink the data with your published articles. Research data
refers to the results of observations or experimentation that validate research findings. To facilitate
reproducibility and data reuse, this journal also encourages you to share your software, code, models,
algorithms, protocols, methods and other useful materials related to the project.
Below are a number of ways in which you can associate data with your article or make a statement
about the availability of your data when submitting your manuscript. If you are sharing data in one of
these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to
the "References" section for more information about data citation. For more information on depositing,
sharing and using research data and other relevant research materials, visit the research data page.
Data linking
If you have made your research data available in a data repository, you can link your article directly to
the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with
relevant repositories, giving readers access to underlying data that gives them a better understanding
of the research described.

There are different ways to link your datasets to your article. When available, you can directly link
your dataset to your article by providing the relevant information in the submission system. For more
information, visit the database linking page.
For supported data repositories a repository banner will automatically appear next to your published
article on ScienceDirect.
In addition, you can link to relevant data or entities through identifiers within the text of your
manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053;
PDB: 1XFN).
Mendeley Data
This journal supports Mendeley Data, enabling you to deposit any research data (including raw and
processed data, video, code, software, algorithms, protocols, and methods) associated with your
manuscript in a free-to-use, open access repository. Before submitting your article, you can deposit
the relevant datasets to Mendeley Data. Please include the DOI of the deposited dataset(s) in your
main manuscript file. The datasets will be listed and directly accessible to readers next to your
published article online.
For more information, visit the Mendeley Data for journals page.
Data statement
To foster transparency, we encourage you to state the availability of your data in your submission.
This may be a requirement of your funding body or institution. If your data is unavailable to access
or unsuitable to post, you will have the opportunity to indicate why during the submission process,
for example by stating that the research data is confidential. The statement will appear with your
published article on ScienceDirect. For more information, visit the Data Statement page.
AFTER ACCEPTANCE
Online proof correction
To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof
corrections within two days. Corresponding authors will receive an e-mail with a link to our online
proofing system, allowing annotation and correction of proofs online. The environment is similar to
MS Word: in addition to editing text, you can also comment on figures/tables and answer questions
from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing
you to directly type your corrections, eliminating the potential introduction of errors.
If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions
for proofing will be given in the e-mail we send to authors, including alternative methods to the online
version and PDF.
We will do everything possible to get your article published quickly and accurately. Please use this
proof only for checking the typesetting, editing, completeness and correctness of the text, tables and
figures. Significant changes to the article as accepted for publication will only be considered at this
stage with permission from the Editor. It is important to ensure that all corrections are sent back
to us in one communication. Please check carefully before replying, as inclusion of any subsequent
corrections cannot be guaranteed. Proofreading is solely your responsibility.
Reprints
Reprints are made available to authors for a nominal charge. Individuals wishing to obtain reprints of
an article that appeared in Comprehensive Psychiatry may do so by contacting the author.
AUTHOR INQUIRIES
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from
Frequently Asked Questions to ways to get in touch.
You can also check the status of your submitted article or find out when your accepted article will
be published.
© Copyright 2018 Elsevier | https://www.elsevier.com

Treatment in Schizophrenia: Factors For Adherence: Francisca Caiado de Bragança

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Treatment in Schizophrenia: Factors For Adherence: Francisca Caiado de Bragança

Uploaded by

Copyright:

Available Formats

2019/2020

Francisca Caiado de Bragança

Mestrado Integrado em Medicina

Área: Psiquiatria e Saúde Mental

Trabalho efetuado sob a Orientação de:

Trabalho organizado de acordo com as normas da revista:

Francisca Caiado de Bragança1, Manuel António Fernandez Esteves2

Keywords: schizophrenia; adherence; antipsychotics.

Schizophrenia is a disabling chronic illness that affects aproximatelly 0,5%-0,7%

3.1. Disease-related factors

3.1.1. Illness duration

A shorter illness duration was found to be significantly associated with higher

The efficacy of antipsychotics in decreasing symptom burden is consistently

Some patients describe psychosis as fascinating, with an undisputable risk of attachment

3.1.3. Neurocognitive dysfunction

Cognitive dysfunction is a robust feature of schizophrenia and has been pointed

3.1.4. Insight level

Patients exhibiting high hostility were found to be less adherent to treatment.30 25

There are conflicting results regarding the relationship between demographic

3.2.2. Adherence background

Previous non-adherence to medication is also an important factor impacting

3.2.3. Alcohol and drug use

3.2.4. Social functioning

In the context of schizophrenia, being socially active relates to better adherence

3.2.6. Attitudes toward medication

3.3.1. Living area

Improved medication adherence has been observed in schizophrenic patients

3.3.3. Stigma and support from others

3.4. Hospitalizations and medication-related factors

Non-adherence is more frequent in patients with multiple past and short-duration

3.4.2. Medication side-effects

3.4.3. First- and second-generation antipsychotics

adherence was reported to be significantly higher when using typical antipsychotics,23

3.4.4. Oral and long-acting injectable (LAI) antipsychotics

3.4.5. Medication scheme

First episode and multiepisode schizophrenia patients seem to have different

3.6. Persistent refusal

While most non-adherent patients may be partially non-adherent, there is an

Adherence is a complex topic mainly because benefits and disadvantages of

1. American Psychiatry Association Apa. DSM-V-TR - Manual Diagnóstico e Estatístico de

Ao Sr. Prof. Doutor Manuel Esteves pela orientação, disponibilidade e dedicação na

Aos meus pais, por tudo.

AUTHOR INFORMATION PACK

TABLE OF CONTENTS XXX

2018: 2.586 © Clarivate Analytics Journal Citation Reports 2019

ABSTRACTING AND INDEXING

AUTHOR INFORMATION PACK 7 Feb 2020 www.elsevier.com/locate/comppsych 1

AUTHOR INFORMATION PACK 7 Feb 2020 www.elsevier.com/locate/comppsych 2

Ensure that the following items are present:

All necessary files have been uploaded:

For further information, visit our Support Center.

BEFORE YOU BEGIN

AUTHOR INFORMATION PACK 7 Feb 2020 www.elsevier.com/locate/comppsych 3

AUTHOR INFORMATION PACK 7 Feb 2020 www.elsevier.com/locate/comppsych 4

AUTHOR INFORMATION PACK 7 Feb 2020 www.elsevier.com/locate/comppsych 5

AUTHOR INFORMATION PACK 7 Feb 2020 www.elsevier.com/locate/comppsych 6

AUTHOR INFORMATION PACK 7 Feb 2020 www.elsevier.com/locate/comppsych 7

A detailed guide on electronic artwork is available.

AUTHOR INFORMATION PACK 7 Feb 2020 www.elsevier.com/locate/comppsych 8

AUTHOR INFORMATION PACK 7 Feb 2020 www.elsevier.com/locate/comppsych 9

AUTHOR INFORMATION PACK 7 Feb 2020 www.elsevier.com/locate/comppsych 10

AUTHOR INFORMATION PACK 7 Feb 2020 www.elsevier.com/locate/comppsych 11

You might also like